---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-024283"
form_type: "8-K"
ticker: "SNWV"
cik: "0001417663"
company_name: "SANUWAVE Health, Inc."
filed_at: "2023-05-12T23:59:59+00:00"
generated_at: "2026-06-15T02:20:35.255138+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# SANUWAVE Q1 revenue up 18% to $3.8M; operating loss flat at $2.0M

## Summary
- Revenue $3.8M (+18% YoY) within prior guidance; gross margin fell to 67% from 72%.
- UltraMist systems sold 28 (+12% YoY); applicator cases 3,641 (+18% YoY).
- Operating loss $2.0M, unchanged YoY; no net income/(loss) figure disclosed.
- Post-quarter raised ~$1.2M via terms consistent with prior financing; funds not in Q1 statements.
- Q2 revenue growth guided to 15-25% YoY, citing improving inventory supply.

## SEC filing metadata
- accession: 0001140361-23-024283
- form_type: 8-K
- ticker: SNWV
- cik: 0001417663
- company_name: SANUWAVE Health, Inc.
- filed_at: 2023-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1417663/000114036123024283/0001140361-23-024283-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1417663/000114036123024283/brhc20052858_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-024283
- JSON: https://secwatch.observer/filing/0001140361-23-024283.json
- Plain text: https://secwatch.observer/filing/0001140361-23-024283.txt

## Key facts
- Earnings Releases
  SANUWAVE Health, Inc. reported first quarter ended March 31, 2023 results: revenue $3.8 million. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2023
  - Revenue: $3.8 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced 1st quarter 2023 results. For the three-months ended March 31, 2023: • Revenues increased 18% to $3.8 million for Q1 2023 versus $3.2 million for the same period last year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1417663/000114036123024283/0001140361-23-024283-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.